du123015  (Solvay Pharmaceuticals)

Journal: BMC Neuroscience

Article Title: Neither in vivo MRI nor behavioural assessment indicate therapeutic efficacy for a novel 5HT 1A agonist in rat models of ischaemic stroke

doi: 10.1186/1471-2202-10-82

Figure Lengend Snippet: Neuroprotective efficacy of 5HT1A agonist DU123015 and positive control MK-801 in the 120 minutes distal MCAo model . The body weights (absolute weight in grams ± SEM) did not differ significantly for DU123015- (A) or MK-801-treated subjects (B). (C) No significant differences on neurological deficit were found for DU123015- (D) or MK-801-treated animals (E). No significant differences between groups were observed for oedema corrected MRI lesion volumes for DU123015-treated animals and glucosaline control treated animals (F). Also, no significant reduction in lesions was detected using the positive control compound MK-801.

Article Snippet: A stock solution of DU123015 (Solvay Pharmaceuticals, Netherlands), was prepared daily at 4.4 mg/ml using sterile water by an experimenter that was not involved in the administration of the compound.

Techniques: Positive Control

Journal: BMC Neuroscience

Article Title: Neither in vivo MRI nor behavioural assessment indicate therapeutic efficacy for a novel 5HT 1A agonist in rat models of ischaemic stroke

doi: 10.1186/1471-2202-10-82

Figure Lengend Snippet: Neuroprotective efficacy of the 5HT1A agonist DU123015 and positive control MK-801 in the 60 minutes distal MCAo model . (A) The body weights of animals treated with DU123015 and glucosaline-treated controls. No significant differences between groups were observed. (B) The body weights for MK-801 and saline-treated controls. No significant differences between groups were observed. Neither DU123015 (C), nor MK-801 (D), significantly improve neurological functions, although on day 2 MK-801 almost significantly improved function (P = 0.056). (E) Oedema corrected MRI lesion volumes did not differ for DU123015-treated animals and glucosaline controls. (F) MK-801-treated animals exhibited a significant reduction in lesion volume at both time-points. (**) P < 0.01, (*) P < 0.05.

Article Snippet: A stock solution of DU123015 (Solvay Pharmaceuticals, Netherlands), was prepared daily at 4.4 mg/ml using sterile water by an experimenter that was not involved in the administration of the compound.

Techniques: Positive Control

Journal: BMC Neuroscience

Article Title: Neither in vivo MRI nor behavioural assessment indicate therapeutic efficacy for a novel 5HT 1A agonist in rat models of ischaemic stroke

doi: 10.1186/1471-2202-10-82

Figure Lengend Snippet: Neuroprotective efficacy of 5HT1A agonist DU123015 and positive control MK-801 in the 90 minutes Intra-Luminal Tread (ILT) model of MCAo . The body weights of animals treated with DU123015 (A) and MK-801 (B). (C) No significant differences were observed on neurological functions in animals treated with DU123015 (D) A Kruskall-Wallis non-parametric test indicated that MK-801 improved neurological functions impaired by stroke. (E) No significant differences were observed on oedema corrected MRI lesion volume for DU123015-treated animals. (F) In contrast, MK-801 significantly reduced lesion volume at all time points (*) P < 0.05 (**) P < 0.01.

Article Snippet: A stock solution of DU123015 (Solvay Pharmaceuticals, Netherlands), was prepared daily at 4.4 mg/ml using sterile water by an experimenter that was not involved in the administration of the compound.

Techniques: Positive Control

Journal: BMC Neuroscience

Article Title: Neither in vivo MRI nor behavioural assessment indicate therapeutic efficacy for a novel 5HT 1A agonist in rat models of ischaemic stroke

doi: 10.1186/1471-2202-10-82

Figure Lengend Snippet: Bilateral Asymmetry Test (BAT) for 90 minutes intra-luminal thread model of MCAo . DU123015 did not improve the total time taken to remove sticky tape from forepaws (A), whereas MK-801 did significantly improved outcome (B) Difference between removal of the sticky tape from the right and left forepaws (L-R) did not improve with DU123015 treatment (C), whereas MK-801 did (D).

Article Snippet: A stock solution of DU123015 (Solvay Pharmaceuticals, Netherlands), was prepared daily at 4.4 mg/ml using sterile water by an experimenter that was not involved in the administration of the compound.

Techniques: